Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II
PLOS One · 2025
DOI: 10.1371/journal.pone.0310485 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Alex J Shamoun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Mucopolysaccharidosis II, Enzyme Replacement Therapy, Iduronate Sulfatase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Takeda Pharmaceuticals U.S.A..
Abstract (Originalsprache)
Mucopolysaccharidosis Type II is a hereditary lysosomal storage disease characterized by deficiency in the enzyme iduronate 2-sulfatase (IDS). IDS is critical in the breakdown of sulfated glycosaminoglycans and its deficiency leads to an accumulation of these compounds across various tissue types resulting in multisystemic dysfunction. Intravenous administration of recombinant IDS (idursulfase) substantially improves patients’ quality and length of life. However, recombinant IDS delivered intravenously is sequestered in the liver and respiratory failure remains as the leading cause of death for patients independent of idursulfase treatment, which suggests insufficient delivery to the lungs. This study aimed to assess a novel method of idursulfase administration using a nebulizer in combination with intravenous treatment and determine if this combination may improve lung delivery of idursulfase and overall pathology. Whole body IDS knockout mice underwent twelve weeks of intravenous, combination treatment, or vehicle injection and we harvested liver and lungs seven days after the last treatment for assessment of IDS activity, histological markers, and global proteomics for comparison with wild-type mice. Combination treatment increased IDS enzyme activity in the liver but not lungs Proteomics data demonstrated attenuation of key features of the disease in liver (metabolic pathways) and lungs (glycosaminoglycan pathways) with both treatments. Overall, adding nebulized administration of IDS did not lead to sustained increase in enzyme activity in the lungs but caused persistent modifications in glycosaminoglycan degradation pathway suggesting additional benefits to intravenous administration alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.
- Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida, United States of America.
- Rare Diseases Unit, Sanofi, Cambridge, Massachusetts, United States of America.
- Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, United States of America.
ORCID-Profile: Gisienne Reis, Leonardo F Ferreira
Förderung
- NHLBI NIH HHS
- Takeda Pharmaceuticals U.S.A.
Zitieren
APA
Shamoun, A. J., Reis, G., Ashley, M., Labilloy, A., & Ferreira, L. F. (2025). Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II. PLOS One. https://doi.org/10.1371/journal.pone.0310485
Vancouver
Shamoun AJ, Reis G, Ashley M, Labilloy A, Ferreira LF. Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II. PLOS One. 2025. doi:10.1371/journal.pone.0310485
BibTeX
@article{Shamoun2025,
author = {Shamoun, Alex J and Reis, Gisienne and Ashley, Malaica and Labilloy, Anatalia and Ferreira, Leonardo F},
title = {Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0310485}
}
EUVIMED